Video

Dr. Sartor on Implications of PSMA-PET Positivity in Prostate Cancer

A. Oliver Sartor, MD, discusses the implications of prostate-specific membrane antigen-PET positivity in prostate cancer.

A. Oliver Sartor, MD, professor of medicine, medical director, Tulane Cancer Center, and C. E. and Bernadine Laborde Professor of Cancer Research, Departments of Medicine and Urology, Tulane University, discusses the implications of prostate-specific membrane antigen (PSMA)-PET positivity in prostate cancer.

Antiandrogen agents such as enzalutamide (Xtandi), apalutamide (Erleada), and darolutamide (Nubeqa) have shown improved metastasis-free survival in patients with nonmetastatic castration-resistant prostate cancer (CRPC).

However, a retrospective analysis of 200 patients with nonmetastatic CRPC showed that 98% of men were PSMA-PET positive. Moreover, 55% of men who had negative conventional imaging had M1 disease according to PSMA-PET.

PSMA-PET positivity may inform other potential treatment options for patients, explains Sartor. For example, patients with metastatic disease could receive radiotherapy while patients with localized disease could receive radiotherapy and potentially surgery.

Additional data regarding PSMA-PET is necessary in this space; however, new imaging modalities are expected to influence the treatment of patients with prostate cancer, concludes Sartor.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity